Goldman Sachs Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $725
Benzinga Newsdesk 16 hours ago
Analyst RatingsNewsPrice TargetHot
Goldman Sachs analyst Salveen Richter maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $654 to $725.
Goldman Sachs analyst Salveen Richter maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $654 to $725.